Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass.,
Clinical data from patients treated in the Phase 1/2/3 RUBY trial of reni-cel in patients with severe sickle cell disease and in the Phase 1/2 EdiTHAL trial of reni-cel in patients with transfusion-dependent beta thalassemia will be shared, including:
- RUBY trial, Abstract #S285, oral presentation on
Saturday, June 15 :- Clinical data on at least 18 patients, with 2-21 months follow-up.
- Efficacy data, including total hemoglobin, fetal hemoglobin, and vaso-occlusive events (VOEs).
- Safety data, including neutrophil and platelet engraftment.
- EdiTHAL trial, Abstract #P1476, poster presentation on
Friday, June 14 :- Clinical data on seven patients, with 4-12 months follow-up.
- Efficacy data, including total hemoglobin, fetal hemoglobin, and transfusion independence.
- Safety data, including neutrophil and platelet engraftment.
“We are making significant progress with the continued development of reni-cel, and we look forward to sharing clinical data, including longer follow up of the dosed patients from the RUBY and EdiTHAL trials next month at the
The abstracts can be accessed on the EHA website.
Oral Presentation Details:
Title: Reni-cel, the first AsCas12a gene-edited cell therapy, led to hemoglobin normalization and increased fetal hemoglobin in severe sickle cell disease patients in an interim analysis of the RUBY trial
Presenting Author:
Date/Time:
Location: Hall Velasquez, IFEMA MADRID Recinto Ferial (Fairgrounds)
Session: s425 Gene therapy, cellular immunotherapy and vaccination – Clinical
Poster Presentation Details:
Title: Reni-cel, the first AsCas12a gene-edited cell therapy, shows promising preliminary results in key clinical outcomes in transfusion-dependent beta-thalassemia patients treated in the EdiThal trial
Presenting Author:
Date/Time:
Location: Hall 7, IFEMA MADRID Recinto Ferial (Fairgrounds)
Session: Poster Session
Reni-cel is currently being investigated in a clinical study in patients with severe sickle cell disease (RUBY trial, NCT04853576) and transfusion-dependent beta thalassemia (EDITHAL trial, NCT05444894). In addition to the clinical data update from the RUBY trial and the EdiTHAL trial at EHA next month, the Company will present a further clinical update from both trials by year-end.
About renizgamglogene autogedtemcel (reni-cel)
Reni-cel, formerly known as EDIT-301, is an experimental gene editing medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Reni-cel consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, where naturally occurring fetal hemoglobin (HbF) inducing mutations reside, by AsCas12a, a novel, proprietary, highly efficient, and specific gene editing nuclease. Red blood cells derived from reni-cel CD34+ cells demonstrate a sustained increase in fetal hemoglobin production, which has the potential to provide a one-time, durable treatment benefit for people living with severe SCD and TDT.
About the RUBY Trial
The RUBY trial is a single-arm, open-label, multi-center Phase 1/2 study designed to assess the safety and efficacy of reni-cel in patients with severe sickle cell disease. Enrolled patients will receive a single administration of reni-cel. The RUBY trial marks the first time AsCas12a was used to successfully edit human cells in a clinical trial. Additional details are available on www.clinicaltrials.gov (NCT04853576).
About the EdiTHAL Trial
The EdiTHAL trial is a single-arm, open label, multi-center Phase 1/2 study designed to assess the safety and efficacy of reni-cel in patients with transfusion-dependent beta thalassemia. Patients will receive a single administration of reni-cel. Additional details are available on www.clinicaltrials.gov (NCT05444894).
About Editas Medicine
As a clinical-stage gene editing company,
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the timing for the Company’s receipt and presentation of data from its clinical trials, including presenting additional clinical data from the RUBY and EdiTHAL trials by year-end 2024, and the potential of, and expectations for, the Company’s product candidates. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of clinical trials, including the RUBY and EdiTHAL trials, and clinical development of the Company’s product candidates, including reni-cel; availability and timing of results from clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the
![](https://ml.globenewswire.com/media/MDVlYjgxM2YtOTEzYS00YjFiLTk0YWQtYTQzZjMyYWUwMmRmLTEwMzc1OTk=/tiny/Editas-Medicine-Inc-.png)
Media and Investor Contact:Cristi Barnett (617) 401-0113 cristi.barnett@editasmed.com
Source: Editas Medicine, Inc.